期刊文献+

血浆五聚素3与慢性肾脏病非透析患者心血管疾病的相关性 被引量:2

Correlation of Pentraxin 3 with cardiovascular disease in chronic kidney disease
下载PDF
导出
摘要 目的探讨血浆五聚素3(pentraxin3,PTX3)水平与慢性肾脏病(CKD)非透析患者心血管疾病(cardio vascular disease,CVD)的关系。方法选择CKD3~5期非透析患者90例分为CKD非CVD组(A组,58例)和CKD合并CVD组(B组,32例);另选健康正常者15名为健康对照组。收集CKD患者临床资料、相关生化指标。用放免法测定PTX3、超敏C反应蛋白(hs—CRP)及彩超测定颈动脉内膜中层厚度(IMT)。采用ROC曲线分析PTX3、hs—CRP与CVD的相关性。相关性分析采用Pearson相关分析法。结果①A、B组PTX3、hS-cRP等炎症介质均明显高于健康对照组(P〈0.05)。②B组PTX3、hs—CRP均明显高于A组(P〈0.05)。③针对CⅧ的ROC曲线分析显示,PTX3与CKD患者的CVD关系更为密切,PTX3曲线下面积为0.860(P〈0.01),当检测的截点为6.73μg/L时,其敏感性为75%,特异性为89.7N;hs—CRP曲线下面积为0.622(P〈0.05),当检测的截点为11.23mg/L时,其敏感性为62.5%,特异性为55.2%。④A、B组IMT均明显高于健康对照组(P〈0.05)。B组比A组IMT呈逐渐增厚趋势,但无统计学意义(P〉0.05)。IMT与PTX3呈正相关(r=0.372,P〈0.05)。结论CKD患者体内都存在炎症状态,PTX3、hs—CRP均高于健康人。与CRP相比,PTX3与CKD患者的CVD关系更为密切。它可作为CKD患者CVD的危险因素观察指标之一。 Objective To investigate the correlation between plasma levels of Pentraxin 3 (PTX3) and cardiovascular disease (CVD) in patients with chronic kidney disease. Methods Ninety patients with chronic kidney disease (stages 3-5) were divided into two groups: non-CVD group A (n = 58) and CVD group B (n = 32). Fifteen healthy volunteers served as control group. Clinical data were collected for analysis. PTX3 and high-sensitive C-reactive protein (hs-CRP)were determined. Carotid intima thickness (IMT) was measured by carotid ultrasound. Receiver operator characteristic (ROC) curve was used to analyze the correlation among PTX3, hsCRP and CVD. Results Plasma PTX3 and hsCRP levels were significantly higher in group 13 than those in group A and control group. ROC curve analysis showed PTX3 was more closely correlated to CVD than hs-CRP in group B. ROC curve of CVD revealed that area under the curve of PTX3 was 0. 860 (P〈0. 01), and that of hs-CRP was 0. 622 (P〈0. 05). With the cut-off value of PTX3 as 6. 73μg/L, the diagnostic sensitivity and specificity in CVD was 75% and 89.7% respectively. With the cut-off value of hs-CRP as 11.23 rag/L, the diagnostic sensitivity and specificity in CVD was 62. 5% and 55.2% respectively. Plasma PTX3 was found to be positively associated with IMT (r = 0. 372, P〈0. 05). Conclusions Chronic inflammation exists in patients with chronic kidney disease. Plasma PTX3 and hs-CRP levels were significantly higher in chronic kidney disease than those in control group. Plasma PTX3 is more related to CVD than hs-CRP in chronic kidney disease with CVD, and it can be a useful marker of CVD risk factors in chronic kidney disease.
出处 《临床肾脏病杂志》 2013年第5期211-214,共4页 Journal Of Clinical Nephrology
基金 上海市黄浦区卫生局科研项目N0:2009HGG-21
关键词 心血管疾病 血浆五聚素3 C反应蛋白质 肾脏病 Cardiovascular disease Pentraxin 3 C-reactive protein Nephrology
  • 相关文献

参考文献16

  • 1Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in china.- A cross-sectional survey. The Lancet. 2012,379 : 815-22.
  • 2钱家麒,姚强.慢性肾衰竭透析患者中炎症发生的原因和后果[J].中国中西医结合肾病杂志,2005,6(8):435-437. 被引量:14
  • 3杨林,李赟.慢性肾心综合征的防治[J].临床肾脏病杂志,2012,12(10):438-440. 被引量:3
  • 4Yilmaz MI, Axelsson J, Sonmez A, et al. Effect of rennin angio- tensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Nephrol, 2009,4: 535-541.
  • 5Mantovani A,Garlanda C,Doni A,et al. Pentraxins in innate im- munity:From C-reative protein to the long pentraxin PTX3. J Clin Immuno,2008,128 : 1-13.
  • 6Tong M, Carrero J J, Qureshi AR, et al. Plasma pentraxin 3 in pa- tients with chronic kidney disease: Associations with renal func- tion,protein-energy wasting cardiovascular disease, and mortali ty. Clin J Am Soc Nephrol, 2007,2 : 889-897.
  • 7Suliman ME, Yilmaz MI, Carrero JJ, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Neph- rol, 2008,3 : 976-985.
  • 8刘丹,郭富强.正五聚体蛋白3与动脉粥样硬化的炎症反应研究进展[J].中华老年医学杂志,2012,31(1):79-81. 被引量:2
  • 9Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the cross- roads between innate immunity, inflammation, matrix deposition, and female fertility. Annual Rev Immunol, 2005,23 : 337 366.
  • 10周懿君,倪兆慧,张纪蔚,张伟明,顾乐怡,吴青伟,沈桂娟,王咏梅,钱家麒.血浆五聚素3水平在血液透析患者外周动脉疾病中的意义[J].中华肾脏病杂志,2009,25(11):821-826. 被引量:4

二级参考文献61

  • 1刘华,方唯一,袁方,关韶峰,张敏.Pentraxin 3蛋白在兔动脉粥样硬化斑块中的表达研究[J].上海交通大学学报(医学版),2011,31(3):271-274. 被引量:10
  • 2Go AS,Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med, 2004, 351: 1296-1305.
  • 3Liew YP, Bartholomew JR, Demirjian S, et al. Combined effect of chronic kidney disease and peripheral arterial disease of all-cause mortality in a high-risk population. Clin J Am Soe Nephrol, 2008, 3:1084-1089.
  • 4Stenvinkcl P, Carrero J J, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol, 2008, 3: 505-521.
  • 5Cazzavillan S, Ratanarat R, Segala C, et al. Inflammation and subc, linical infection in chronic kidney disease: a molecular approach. Blood Purif, 2007, 25: 69-76.
  • 6He X, Han B, Liu M. Long pentraxin PTX3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol, 2007, 292: LI039-LI049.
  • 7Boehme M, Kaehne F, Kuehne A, et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrnl Dial Transplant, 2007, 22: 2224 - 2229.
  • 8Suliman ME, Qureshi AR, Carrero J J, et al. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. Q J Med,2008, 101 : 397-405.
  • 9Selvin E,Erlinger TP. Prevalence and risk factors for peripheral arterial disease in the US: Results from the National Health and Nutrition Examination Survey (NHANES). 1999-2000. Circulation, 2004, 110: 738-743.
  • 10Belch JJ,Topol EJ,Agnelli G,et al. Critical issues in peripileral arterial disease detection and management: a call to action. Arch Intern Med, 2003, 163: 884-892.

共引文献19

同被引文献56

  • 1张敏芳,钱家麒,徐筱琪,戴慧莉,吴青伟,倪兆慧.慢性肾衰竭患者血清骨保护素浓度与心脏瓣膜钙化的关系[J].中华肾脏病杂志,2007,23(10):626-630. 被引量:5
  • 2Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiolo- of cardiovascular disease in chronic renal disease-J_ Am J Kidney Dis, 1998, 32(5 Suppl 3): S112 -119.
  • 3Gusbeth - Tatomir P, Covic A. Causes and consequences of increased arterial stiffness in chronic kidney disease patients [ J ]. Kidney Blood Press Res ,2007,30 ( 2 ) : 97 - 107.
  • 4Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging bi- omarkers ibr evaluating cardiovascular risk in the chron- ic kidney disease patient:how do new pieces fit into the uremic puzzle[ J ]. Clin J Am Soc Nephrol, 2008,3 (2) :505 -521.
  • 5Stam F, van Guldener C, Becker A, et al. Endothelial dvsfunction contributes to renal function- associated cardiovascular mortality in a population with mild renal insufficiency: the Hoom study [ J]. Am Soc Nephrol, 2006,17(2) :537 -545.
  • 6Siasos G, Tousoulis D, Michalea S, et al. Biomarkers determining cardiovascular risk in patients with kidney disease[ J]. Curr Med Chem, 2012, 19 ( 16 ) : 2555 - 2571.
  • 7Wald DS, Law M, Morris JK. Homocysteine and cardi- ovascular disease:evidence on causality from a meta - analysis [ J ]. BMJ ,2002,325 ( 7374 ) : 1202.
  • 8Balsam A, E1 Kossi MM, Lord R, et al. Cardiovascular disease on hemodialysis: predictors of atherosclerosis and survival [ J ]. Hemodial Int, 2009, 13 ( 3 ) : 278 - 285.
  • 9Jamison RL, Hartigan P, Kaufman JS, et al. Effect of ho- mocvsteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renaldisease: a randomized controlled trial [J ]. JAMA, 2007,298(10) :1163 - 1170.
  • 10Liu C, Wang Q, Guo H, et al. Plasma S - adenosylhomo- cvsteine is a better biomarker of atherosclerosis than ho- mocvsteine in apolipoprotein E-deficient mice fed high dietary methionine [ J ]. J Nutr, 2008,138 ( 2 ) : 311 -315.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部